Free Biopharma Daily Stock Updates - 06/15/21

$XBI $133.43 -2.4%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$MRNA -2.8% Moderna and Magenta Partner to Distribute Moderna’s COVID-19 Vaccine and Updated Variant Booster Candidates in United Arab Emirates. source

$OCGN +2.1% Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™. source

$AZN +0.1% COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant. source

$AZN +0.1% Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19. source

Pipeline Updates

$APTX -0.3% Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder. source

$ETON +4.8% Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector. source

$SWTX -1.2% SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference. source

$SPRO -2.9% Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206. source

$SYBX -1.8% Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference. source

$ETON +4.8% Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection). source

$BCLI +1.5% Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets. source

$ATNM -1.5% Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B presented at the 2021 Virtual SNMMI Conference. source

$ATNM -1.5% Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receiving Iomab-B Presented at 2021 SNMMI Virtual Conference. source

$JNCE +8.1% Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody. source

$CYTK +2.0% Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction. source

$OTIC +0.4% Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss. source

$CRSP -4.0% CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia. source

$VECT +0.7% VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure. source

$CLSD +37.8% Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD. source

$IBRX -3.3% FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer. source

$AXSM -0.5% Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia. source

$AUTL -4.2% Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL. source

$CERE -1.6% Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy. source

$SAGE -19.3% Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder. source

$AVXL -17.4% Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer’s Disease source

$FUSN +18.1% Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434. source

$CTXR +17.5% Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS. Source

Financial Updates

$PTGX -7.2% Protagonist Therapeutics Announces Proposed Public Offering of Common Stock. source

$PDSB -28.5% PDS Biotech Prices Public Offering of Common Stock. source

$ENOB -12.5% Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules. source

---

Posted by FS